Giles Turner, from Sussex, is paying for abiraterone privately at a cost of £250 per month Thousands of patients in England and Northern Ireland are missing out on a life-extending prostate ...

Abiraterone is one of the ICR’s biggest success stories – the first treatment shown to be effective in men with advanced prostate cancer. In 2012 it was made available on the NHS, at a stroke ...

Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...

This Prostate Cancer Awareness Month, we’re celebrating over 10 years since abiraterone was first recommended by NICE in England as a treatment for advanced prostate cancer. Diana Cano, Ichha Khanal, ...

2024年，制药行业迎来了机遇与挑战并存的复杂局面。近期的科学突破不断带来新的治疗方案，但政府法规、飙升的成本、沉重的患者负担，以及全球紧张局势等因素抑制了投资者的热情。基于以上背景，AdisInsight推出了一份专题报告《突破性疗法与重磅药物：新 ...

Future Oncol. 2010;6(5):665-679. Three Phase I studies by O'Donnell and colleagues have reported the pharmacodynamic activity of abiraterone acetate, which was originally developed as an oral ...

Explore our latest breakthroughs in metastatic prostate cancer research. Learn more about our innovative pipeline today! @ ...

Pfizer’s Talzenna-Xtandi combination has marked a major step forward in treating advanced prostate cancer, improving patient ...

Abiraterone acetate is used along with prednisolone (corticosteroid) for treating a type of prostate cancer called metastatic castration-resistant prostate cancer (mCRPC) previously called hormone ...

Future Oncol. 2015;11(1):91-106. Abiraterone was investigated in Phase I/II study in chemotherapy-naive CRPC patients: in this trial, a decline in PSA of ≥50% was observed in 67% of patients ...

In the mHSPC setting, treatment approaches are rapidly evolving, sparking ongoing debate among clinicians about the efficacy ...